• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?

作者信息

Paulino Eduardo, de Melo Andreia Cristina

机构信息

Brazilian National Cancer Institute and Grupo Oncoclínicas, Rio de Janeiro, Brazil.

出版信息

J Gynecol Oncol. 2020 Nov;31(6):e95. doi: 10.3802/jgo.2020.31.e95.

DOI:10.3802/jgo.2020.31.e95
PMID:33078600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7593230/
Abstract
摘要

相似文献

1
Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?奥拉帕利与贝伐单抗用于卵巢癌一线维持治疗：PAOLA-1试验未充分赋权亚组分析中的过度依赖？
J Gynecol Oncol. 2020 Nov;31(6):e95. doi: 10.3802/jgo.2020.31.e95.
2
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.在 III 期 PAOLA-1/ENGOT-ov25 试验中，根据新诊断的晚期卵巢癌患者的临床风险，维持奥拉帕利联合贝伐珠单抗的疗效。
Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22.
3
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.基于分子分类的维持治疗在原发性上皮性卵巢癌治疗后的美国成本效益分析。
JAMA Netw Open. 2020 Dec 1;3(12):e2028620. doi: 10.1001/jamanetworkopen.2020.28620.
4
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.奥拉帕利联合贝伐珠单抗作为新诊断晚期卵巢癌患者的维持治疗：来自 PAOLA-1/ENGOT-ov25 试验的日本亚组。
J Gynecol Oncol. 2021 Sep;32(5):e82. doi: 10.3802/jgo.2021.32.e82.
5
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.奥拉帕利联合贝伐珠单抗作为分子状态的晚期卵巢癌一线维持治疗：基于 PAOLA-1 的成本效果更新分析。
J Gynecol Oncol. 2024 Jan;35(1):e2. doi: 10.3802/jgo.2024.35.e2. Epub 2023 Jul 5.
6
The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.奥拉帕利联合贝伐珠单抗维持治疗晚期卵巢癌的成本效果分析：基于 PAOLA-1 研究的最终生存结果。
J Ovarian Res. 2023 Aug 21;16(1):168. doi: 10.1186/s13048-023-01257-4.
7
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
8
Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.晚期卵巢癌患者治疗管理的差异：一项针对五个国家肿瘤学家的调查
Drug Des Devel Ther. 2017 Dec 6;11:3471-3479. doi: 10.2147/DDDT.S151420. eCollection 2017.
9
Regulatory considerations on endpoints in ovarian cancer drug development.卵巢癌药物研发中终点指标的监管考量
Cancer. 2017 Jul 15;123(14):2604-2608. doi: 10.1002/cncr.30652. Epub 2017 May 12.
10
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.奥拉帕利单药维持治疗铂敏感复发性浆液性卵巢癌患者的总生存期：一项随机、安慰剂对照、双盲、2 期临床试验的更新分析。
Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.

本文引用的文献

1
Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.基于同源重组缺陷状态的高级别浆液性卵巢癌分类。
Sci Rep. 2020 Feb 17;10(1):2757. doi: 10.1038/s41598-020-59671-3.
2
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
3
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.尼拉帕利联合一线化疗及维持治疗卵巢癌
N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.
4
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
5
Biomarkers for Homologous Recombination Deficiency in Cancer.癌症同源重组缺陷的生物标志物。
J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. doi: 10.1093/jnci/djy085.
6
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.芦卡帕利维持治疗铂类化疗后缓解的复发性卵巢癌（ARIEL3）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.
7
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.尼拉帕利维持治疗铂敏感复发性卵巢癌。
N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
8
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.同源重组缺陷（HRD）评分可预测三阴性乳腺癌患者对含铂新辅助化疗的反应。
Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.
9
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.基因组杂合性丢失模式预测上皮性卵巢癌同源重组修复缺陷。
Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.
10
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.倍性和大规模基因组不稳定性一致鉴定出具有 BRCA1/2 失活的基底样乳腺癌。
Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.